Tofacitinib for the Treatment of Nail Lesions and Palmoplantar Pustulosis in Synovitis, Acne, Pustulosis, Hyperostosis, and Osteitis Syndrome.

ABSTRACT:

Importance

Nail involvement is common in synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome, which has a strong association with quality of life in patients with SAPHO. Tofacitinib is an oral Janus kinase inhibitor that has been previously shown to be effective for nail psoriasis.

Objective

To assess the efficacy and safety of tofacitinib for the treatment of nail involvement in SAPHO syndrome.

Interventions

Participants received tofacitinib, 5 mg, twice daily, for 12 weeks.

Design, setting, and participants

This open-label, single-arm, prospective pilot study included 13 patients with SAPHO syndrome accompanied by nail lesions and active palmoplantar pustulosis who were recruited from Peking Union Medical College Hospital from September 2

SUBMITTER: Li C 

PROVIDER: S-EPMC7527944 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature